MX2020004536A - Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). - Google Patents
Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).Info
- Publication number
- MX2020004536A MX2020004536A MX2020004536A MX2020004536A MX2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A MX 2020004536 A MX2020004536 A MX 2020004536A
- Authority
- MX
- Mexico
- Prior art keywords
- trka
- inhibitors
- pyrimidine derivatives
- receptor kinase
- tropomyosin receptor
- Prior art date
Links
- 101150111783 NTRK1 gene Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091005682 Receptor kinases Proteins 0.000 title 1
- 102000005937 Tropomyosin Human genes 0.000 title 1
- 108010030743 Tropomyosin Proteins 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 3
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a nuevos inhibidores de TrkA de la formula (1) que son utiles en el tratamiento o prevencion del dolor agudo y cronico, pero tambien para otras actividades anormales de TrkA, mas alla de la terapia del dolor, tales como inflamacion y cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203290 | 2017-11-23 | ||
| PCT/EP2018/082183 WO2019101843A1 (en) | 2017-11-23 | 2018-11-22 | Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004536A true MX2020004536A (es) | 2020-08-03 |
Family
ID=60484137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004536A MX2020004536A (es) | 2017-11-23 | 2018-11-22 | Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200399250A1 (es) |
| EP (1) | EP3672957A1 (es) |
| JP (1) | JP2021504462A (es) |
| KR (1) | KR20200090198A (es) |
| CN (1) | CN111247139A (es) |
| BR (1) | BR112020010120A2 (es) |
| CA (1) | CA3076444A1 (es) |
| MX (1) | MX2020004536A (es) |
| RU (1) | RU2020115534A (es) |
| WO (1) | WO2019101843A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ580343A (en) * | 2007-04-13 | 2012-03-30 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors |
| MX2009011811A (es) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| US20130252924A1 (en) * | 2010-11-11 | 2013-09-26 | Akron Molecules Gmbh | Compounds and Methods for Treating Pain |
| CN103622966A (zh) * | 2012-08-24 | 2014-03-12 | 常辉 | 陶扎色替在制备治疗精神分裂症的药物中的用途 |
-
2018
- 2018-11-22 MX MX2020004536A patent/MX2020004536A/es unknown
- 2018-11-22 BR BR112020010120-6A patent/BR112020010120A2/pt not_active Application Discontinuation
- 2018-11-22 RU RU2020115534A patent/RU2020115534A/ru unknown
- 2018-11-22 CA CA3076444A patent/CA3076444A1/en not_active Abandoned
- 2018-11-22 US US16/764,996 patent/US20200399250A1/en not_active Abandoned
- 2018-11-22 CN CN201880068364.XA patent/CN111247139A/zh active Pending
- 2018-11-22 KR KR1020207017424A patent/KR20200090198A/ko not_active Ceased
- 2018-11-22 EP EP18814791.2A patent/EP3672957A1/en not_active Withdrawn
- 2018-11-22 WO PCT/EP2018/082183 patent/WO2019101843A1/en not_active Ceased
- 2018-11-22 JP JP2020545870A patent/JP2021504462A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021504462A (ja) | 2021-02-15 |
| WO2019101843A1 (en) | 2019-05-31 |
| CA3076444A1 (en) | 2019-05-31 |
| EP3672957A1 (en) | 2020-07-01 |
| US20200399250A1 (en) | 2020-12-24 |
| RU2020115534A (ru) | 2021-11-08 |
| BR112020010120A2 (pt) | 2020-11-10 |
| KR20200090198A (ko) | 2020-07-28 |
| CN111247139A (zh) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| CO2020013599A2 (es) | Piridazinonas como inhibidoras de parp7 | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2018000150A1 (es) | Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508) | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| CL2025000629A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| CR20170500A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| ECSP19066721A (es) | Inhibidores duales de magl y faah | |
| MX2018010993A (es) | Derivados de icariina e icaritina. | |
| MX2017005283A (es) | Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| MX2018013519A (es) | Inhibidores del potenciador del homologo zeste 2. | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2020004536A (es) | Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). | |
| MX2018004868A (es) | Derivados de la pirrolidina. |